RT Journal Article
SR Electronic
T1 Clinical and Economic Impact of COVID-19 on Plantation Workers: Preliminary Results from the Guatemala Agricultural Workers and Respiratory Illness Impact (AGRI) Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22270274
DO 10.1101/2022.02.07.22270274
A1 Olson, Daniel
A1 Calvimontes, Diva M.
A1 Lamb, Molly M.
A1 Guzman, Gerber
A1 Barrios, Edgar
A1 Chacon, Andrea
A1 Rojop, Neudy
A1 Arias, Kareen
A1 Gomez, Melissa
A1 Bolanos, Guillermo Antonio
A1 Monzon, Jose
A1 Chard, Anna N.
A1 Iwamoto, Chelsea
A1 Duca, Lindsey M.
A1 Vuong, Nga
A1 Fineman, Melissa
A1 Lesteberg, Kelsey
A1 Beckham, David
A1 Santiago, Mario L.
A1 Quicke, Kendra
A1 Ebel, Gregory
A1 Gutierrez, Emily Zielinski
A1 Azziz-Baumgartner, Eduardo
A1 Hayden, Frederick G.
A1 Mansour, Hani
A1 Edwards, Kathryn
A1 Newman, Lee S.
A1 Asturias, Edwin J.
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270274.abstract
AB We evaluated the clinical and socioeconomic burdens of respiratory disease in a cohort of Guatemalan banana plantation workers. All eligible workers were offered enrollment from June 15–December 30, 2020, and annually, then followed for influenza-like illnesses (ILI) through: 1) self-reporting to study nurses, 2) sentinel surveillance at health posts, and 3) absenteeism. Workers with ILI submitted nasopharyngeal swabs for influenza, RSV, and SARS-CoV-2 testing, then completed surveys at days 0, 7, and 28. Through October 10, 2021, 1,833 workers developed 169 ILIs (12.0/100 person-years) and 43 (25.4%) of these ILIs were laboratory-confirmed SARS-CoV-2 (3.1/100 person-years). Workers with SARS-CoV-2-positive ILI reported more anosmia (p<0.01), dysgeusia (p<0.01), difficulty concentrating (p=0.01), and irritability (p=0.01), and greater clinical and well-being severity scores (Flu-iiQ) than test-negative ILIs; they also had greater absenteeism (p<0.01) and lost income (median US$127.1, p<0.01). These results support the prioritization of Guatemalan farm workers for COVID-19 vaccination.Competing Interest StatementDO receives grant funding from Roche and Sanofi Pasteur. FGH has served as a consultant to Genentech, Roche, Shionogi, and other companies involved in development or marketing of influenza therapeutics or vaccines. He has received honoraria from the University of Alabama Antiviral Drug Discovery and Development Consortium for SAB work and from the World Health Organization for document preparation related to influenza. KME receives grant funding from NIH and CDC, is a consultant to Bionet and IBM, is a member of Data Safety and Monitoring Committees for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche.Funding StatementThis work is funded by the NIH/NIAID 1K23AI143967, CDC-CAR/CGH CDC_GH002243, and Investigator-initiated contributions by Roche Molecular Systems, Roche Diagnostics and Sanofi Pasteur. DO is supported by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082 and the Childrens Hospital of Colorado Research Scholar Award. KQ is supported by NIH 1F32AI150123.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Colorado Multiple Institutional Review Board (COMIRB protocol #19-1836) and the Guatemala Ministry of Health National Ethics Committee (HRMC-560-2020). The local Southwest Trifinio Community Advisory Board for Research agreed to the study. Workers receive no compensation for study participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript